Medical News

RSS

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.

29 Apr 2010

Arthro SupReviver contains vital nutrients for joint pain, aids in weight loss

A unique joint supporter, called Arthro SupReviver, can help people significantly lose weight. Antionette, a registered nurse in central Florida, lost 80 lbs in 8 months while taking Arthro SupReviver for her achy knees.

29 Apr 2010

Imaging costs for Medicare cancer patients on the rise

A study in the Journal of the American Medical Association analyzed data from Medicare cancer patients to determine the change in imaging use for this group.

29 Apr 2010

Obama's debt commission to consider Medicare cuts, new health care law

President Obama's bipartisan debt commission met Tuesday to discuss ways to reduce the federal deficit. The President said that everything was up for discussion, including provisions of the federal health care law, and entitlement programs like Medicare and Social Security.

29 Apr 2010

Vascular surgeon successfully bypasses torn aorta

Rhonda Mullen was 38 years old and in perfect health when she suddenly felt a searing pain between her shoulder blades. A few hours later, Mullen was being wheeled into an operating room at Loyola University Hospital for emergency surgery to repair an unusual tear in her aorta, the body's main blood vessel.

29 Apr 2010

Investigators study Pioglitazone and Vitamin E for treatment of NASH

A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis, according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Results were published April 28 online in the New England Journal of Medicine.

29 Apr 2010

Boston hospital case study in balancing mission and profits

The Boston Globe: A proposed acquisition of Boston's Catholic hospital system Caritas Christi Health Care by private-equity firm Cerberus Capital Management may test the theory that "profitability and religious mission can be integrated." However, another local hospital provides a possible window into that future.

29 Apr 2010

FDA grants Fenwal 510(k) clearance for Amicus separator with DXT

Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance for its Amicus® separator with new wireless data-export capabilities.

29 Apr 2010

Neoprobe reports revenues of $2.7M for first-quarter 2010

Neoprobe Corporation, a diversified developer of innovative biomedical surgical oncology products, today announced consolidated results for the first quarter of 2010. First quarter 2010 revenues were $2.7 million, consistent with the record revenue reported for the first quarter of 2009.

29 Apr 2010

Mylan Pharmaceuticals' ANDA for generic version of Flomax receives FDA approval

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Tamsulosin Hydrochloride Capsules USP, 0.4 mg, the generic version of Boehringer Ingelheim's benign prostatic hyperplasia treatment, Flomax.

29 Apr 2010

Merge Healthcare completes merger agreement with AMICAS

Today's successful close of the merger agreement between Merge Healthcare Incorporated and AMICAS, Inc. creates a leading medical imaging software and healthcare IT solutions provider with strong customer relationships, innovative solutions, significant cross selling capabilities, and a solid international presence.

29 Apr 2010

Goodwin Biotechnology, Hyprocell sign collaborative agreement to strengthen clinical development services

Goodwin Biotechnology Inc., a full service contract biomanufacturing company, and Hyprocell LLC, a clinical cell line development services company, jointly announced today their collaborative agreement to create a business model enabling customers to access their one stop shop services.

28 Apr 2010

Xlumena receives FDA clearance to market NAVIX Access Device

Xlumena, a privately held provider of innovative technology for gastroenterologists/interventional endoscopists, today announced it has received clearance from the US Food and Drug Administration to market its NAVIX Access Device.

28 Apr 2010

Experts disagree on health law's effects on jobs

"There is profound disagreement about healthcare reform's overall impact on jobs. … While the net effect on jobs remains uncertain, it is clear that certain professions will do better than others." Among the specific job categories likely do well are insurance agents, who "may get a boost since approximately 32 million uninsured Americans will be required to buy health insurance starting in 2014.

28 Apr 2010

Many Americans aren't taking necessary steps to protect against diabetes: Study

Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention. However, while nearly 60 percent of Americans are concerned about developing diabetes, many aren't taking the necessary steps to protect their health, according to a recent study by the International Diabetes Center and Abbott.

28 Apr 2010

More taxes and drab packages for cigarettes to deter the young from smoking

From 1st July 2012 companies making cigarettes will be allowed only to have a brand name and a graphic health warning on their cigarette packs. There has been a huge debate over this issue. Trade experts believe that this move could mean that the Federal Government may have to cough up more than $3 billion a year to cigarette companies. Tim Wilson from the Institute of Public Affairs also believes that this would cost taxpayers $3.4 billion a year in compensation to tobacco companies. However Australia will be the first country to introduce such a measure.

28 Apr 2010

Advertising codes failing NZ children

A study conducted at Otago University’s Wellington campus in New Zealand by Louise Thornley and her colleagues has found that the self regulating Advertising Standards Authority is failing to protect children. As per the advertising codes, advertisements are not supposed to target children to encourage consumption of junk food.

28 Apr 2010

Celera reports net loss of $12.5M for first-quarter 2010

Celera Corporation today reported net revenues of $31.4 million for the first quarter of 2010 that ended March 27, 2010, compared to $45.7 million in the prior year quarter. For the first quarter of 2010, Celera reported a net loss $12.5 million, or $0.15 per share, compared to a net loss of $1.4 million, or $0.02 per share, for the prior year quarter.

28 Apr 2010

Seasonal flu shots: Are they responsible for the adverse reactions? Investigations on

After the seasonal flu vaccines caused over 250 cases of fever, vomiting and convulsions and one reported death in under-fives there has been intense investigations to detect the cause. Further vaccinations were stopped last Friday.

28 Apr 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010